摘要
目的分析顺铂＋多西他赛治疗非小细胞型肺癌患者的效果。方法选择2015年1月~2016年6月我院治疗的42例非小细胞型肺癌患者作为研究组,并对2014年2~12月的42例非小细胞型肺癌患者作为对照组,对对照组患者采用吉西他滨联合顺铂治疗,研究组患者采用多西他赛联合顺铂治疗,观察对比两组患者的临床疗效、毒副作用发生情况及平均疾病进展时间、平均生存期。结果研究组患者总有效率为85.71%,较对照组的66.67%明显更高（P〈0.05）;研究组毒副作用发生率与对照组比较,差异无统计学意义（P〉0.05）;研究组患者平均疾病进展时间、平均生存期均优于对照组,差异有统计学意义（P〈0.05）。结论采用顺铂＋多西他赛治疗非小细胞型肺癌效果显著,安全性高,可在临床上推广。
Objective To analyze effect of Cisplatin combined with Docetaxel in the treatment of non small cell lung cancer.Methods 42 patients with non small cell lung cancer treated in our hospital from January 2015 to June 2016 were selected as study group,and 42 patients with non small cell lung cancer from February to December in 2014 as control group.Patients in the control group were given combined treatment of Gemcitabine and Cisplatin,patients in the study group were treated by Docetaxel and Cisplatin,clinical efficacy,toxic and side effect,average disease progress time and average survival time in two groups were observed and compared.Results After treatment,total efficiency rate in the study group was 85.71%,higher than 66.67% in the control group（P〈0.05）;occurrence rate of toxic and side effect in the study group had no significant difference compared with the control group（P〉0.05）;average disease progress time and average survival time in the study group were better than those in the control group（P〈 0.05）.Conclusion Combined treatment of Gemcitabine and Cisplatin in patients with non small cell lung cancer has more significant therapeutic effect and high safety,which can be extended in clinic.
出处
《中国当代医药》
2016年第26期52-53,57,共3页
China Modern Medicine
